Nichols & Pratt Advisers LLP MA Cuts Stake in Pfizer Inc. (NYSE:PFE)

Nichols & Pratt Advisers LLP MA cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,605 shares of the biopharmaceutical company’s stock after selling 1,528 shares during the quarter. Nichols & Pratt Advisers LLP MA’s holdings in Pfizer were worth $1,343,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PFE. Swedbank AB grew its holdings in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares during the last quarter. Financial Advocates Investment Management grew its holdings in shares of Pfizer by 5.5% during the third quarter. Financial Advocates Investment Management now owns 44,909 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 2,361 shares during the last quarter. United Asset Strategies Inc. grew its holdings in shares of Pfizer by 7.1% during the third quarter. United Asset Strategies Inc. now owns 32,274 shares of the biopharmaceutical company’s stock valued at $934,000 after buying an additional 2,141 shares during the last quarter. Reston Wealth Management LLC purchased a new stake in shares of Pfizer during the third quarter valued at $83,000. Finally, Aspen Wealth Strategies LLC lifted its position in Pfizer by 22.0% during the third quarter. Aspen Wealth Strategies LLC now owns 10,207 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 1,843 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim restated a “buy” rating and set a $33.00 target price on shares of Pfizer in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Up 1.3 %

PFE stock opened at $26.43 on Friday. The stock has a market capitalization of $149.78 billion, a P/E ratio of 18.74, a P/E/G ratio of 0.64 and a beta of 0.64. The firm has a 50-day simple moving average of $26.35 and a 200-day simple moving average of $27.34. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.